Brisbane, Australia 4th Feb 2013: Brisbane-based drug discovery and development company Alchemia Limited (ASX: ACL) has recruited the 390th patient to its pivotal Phase III clinical trial of the Company’s lead cancer drug, HA-Irinotecan, as per its study protocol.

The final stage study compares the safety and efficacy of Alchemia’s proprietary HyACT technology in combination with standard chemotherapy drug irinotecan (HA-Irinotecan) against irinotecan alone in metastatic colorectal cancer patients. The double blind trial is being conducted in second and third line patients (mCRC) when administered as part of the FOLFIRI regimen.

As of 31st January 2013 European time, 390 patients had been recruited at 76 sites in Australia, Eastern and Western Europe, since the study began in January 2012.

Other relevant content